

# SEMINARS IN HUMAN AND TRANSLATIONAL IMMUNOLOGY

*Presented by the  
Yale Center for Immuno-Oncology*



**YaleCME**  
CONTINUING MEDICAL EDUCATION

## “MYC drives a molecularly- and metabolically-distinct subset of small cell lung cancer”

**Trudy Oliver, PhD**

Associate Professor with Tenure of Oncological Sciences  
University of Utah  
Huntsman Cancer Institute Endowed Chair in Cancer  
Research

**Tuesday, December 1, 2020**

**4:00 – 5:00pm**

**Zoom – [meeting link](#)**

**By Telephone: 203-432-9666 – Meeting ID: 959 9379 1815 – Psw: HTI**

### **ACCREDITATION**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### **TARGET AUDIENCE**

The target audience for the HTI Seminar Series comprises attending faculty, clinical and basic scientists, community physicians, nurses, residents, fellows, and students.

### **NEEDS ASSESSMENT**

The HTI Seminar Series seeks to review the scientific basis for choice of immunologically related therapeutic targets in various diseases, including organ-specific and systemic autoimmunity, allergy, transplant rejection, cancer, and infectious diseases. The goal is to help understand the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice and review the data on the different therapeutic approaches in different specialties.

### **LEARNING OBJECTIVES**

At the conclusion of this activity, participants will be able to:

1. Describe key features of the major molecular subtypes of small cell lung cancer (SCLC).
2. List therapeutic vulnerabilities that are specific to SCLC molecular subsets.

3. Discuss how cell of origin, genetics, and cell fate plasticity may impact SCLC subtype.

### **DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

### **FACULTY DISCLOSURES**

**Trudy Oliver:** Speaker honorarium from Illumina, Inc.

**Carrie Lucas:** None

**Ellen Foxman:** None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.

*There is no corporate support for this activity*

**Seminar Host: Marcus Bosenberg, MD, PhD**

**Course Directors: Carrie Lucas, PhD and Ellen Foxman, MD, PhD**

For additional information, please contact Allysia Matthews ([allysia.matthews@yale.edu](mailto:allysia.matthews@yale.edu))